Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials-Reference-Cited by-同舟云学术

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

Published:2017-07-21 Issue:11 Volume:19 Page:1529-1536
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

O'Neil Patrick M.¹^ORCID,Aroda Vanita R.²,Astrup Arne³,Kushner Robert⁴,Lau David C. W.⁵,Wadden Thomas A.⁶,Brett Jason⁷,Cancino Ana-Paula⁸,Wilding John P. H.⁹,

Affiliation:

1. Weight Management Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina; Charleston South Carolina

2. Department of Internal Medicine, Endocrinology, Diabetes & Metabolism, MedStar Health Research Institute; Georgetown University School of Medicine; Hyattsville Maryland

3. Department of Nutrition, Exercise and Sports; University of Copenhagen; Frederiksberg C Denmark

4. Department of Internal Medicine, Northwestern University Feinberg School of Medicine; Chicago Illinois

5. Departments of Medicine and Biochemistry & Molecular Biology, University of Calgary Cumming School of Medicine; Calgary Alberta Canada

6. Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania; Philadelphia Pennsylvania

7. Novo Nordisk Inc.; Plainsboro New Jersey

8. Novo Nordisk A/S; Søborg Denmark

9. Department of Obesity and Endocrinology, Obesity and Endocrinology Clinical Research Group; University of Liverpool; Liverpool UK

Funder

Novo Nordisk A/S

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12963/fullpdf

Reference33 articles.

1. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19 · 2 million participants;NCD Risk Factor Collaboration (NCD-RisC);Lancet,2016

2. Ferguson C David S Divine L Obesity drug outcome measures. A consensus report of considerations regarding pharmacologic intervention 2012 http://sphhs.gwu.edu/releases/obesitydrugmeasures.pdf

3. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis;Guh;BMC Public Health,2009

4. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis;Flegal;JAMA,2013

5. Bodyweight, gender, and quality of life: a population-based longitudinal study;Garner;Qual Life Res,2012

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality;JAMA Network Open;2024-08-20

2. Association between glucagon‐like peptide‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database;Diabetes, Obesity and Metabolism;2024-08-19

3. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study;Diabetologia;2024-08-06

4. Glucagon-like peptide receptor agonists and risk for depression;Primary Care Diabetes;2024-08

5. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes;Annals of Internal Medicine;2024-08